Improving treatment access for cystic fibrosis patients
Official title: ENsuring ACcess to optimal Therapy in CF: ENACT study
Funded at Arkansas Children's Hospital Res Inst · NIH-10978628 · Data updated 2026-11-12
This study is looking at how different genes affect how cystic fibrosis patients respond to a new combination therapy, so we can make sure everyone gets the best treatment that works for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arkansas Children's Hospital Res Inst NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project start | July 17, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $642,460 |
| NIH project number | 1R01HL171034-01A1 |
| Project ID | NIH-10978628 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cystic fibrosis who are currently receiving or are eligible for the new combination therapy.
✕Less likely to help
Patients who do not have cystic fibrosis or those who are not receiving the combination therapy may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of a new combination therapy for cystic fibrosis (CF) patients by studying how genetic variations affect drug metabolism. It aims to gather data on how different patients respond to the therapy in real-world settings, particularly looking at drug concentrations and side effects. By understanding these variations, the research seeks to optimize treatment plans for individuals with CF, ensuring they receive the most effective care tailored to their genetic makeup.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for cystic fibrosis patients, improving their health outcomes.
How similar studies have gone: Previous research has shown promising results in optimizing drug therapies through pharmacogenetic approaches, indicating potential success for this study.
Where this research is happening
-
Arkansas Children's Hospital Res Inst
Little Rock, United States Active
Researchers
- Principal investigator: Guimbellot, Jennifer S — Arkansas Children's Hospital Res Inst
- Study coordinator: Guimbellot, Jennifer S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.